REG - Byotrol PLC - Investor Presentation

ByotrolAnnouncement

02/09/2022 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220902:nRSB1044Ya&default-theme=true

RNS Number : 1044Y  Byotrol PLC  02 September 2022

 

 

 

Byotrol plc

("Byotrol" or the "Company")

Investor Presentation

 

Byotrol plc (AIM: BYOT), the developer of anti-microbial technologies, is
pleased to announce that David Traynor, CEO, Chris Sedwell, CFO, and Vivan
Pinto, CGO, will provide a live presentation relating to Final Results
2022 via the Investor Meet Company platform on 15th September 2022 at
11:00am BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet Byotrol plc via:

 

https://www.investormeetcompany.com/byotrol-plc/register-investor
(https://www.investormeetcompany.com/byotrol-plc/register-investor)

 

Investors who already follow Byotrol on the Investor Meet Company platform
will automatically be invited.

 

 

For further information, visit www.byotrolplc.com (http://www.byotrolplc.com)
, follow on twitter @byotrol, or contact

 

Byotrol plc

David Traynor - Chief Executive Officer

Chris Sedwell - Chief Financial
Officer
             01925 742 000

 

finnCap Limited (Nominated Adviser and Broker)

Geoff Nash/James Thompson -  Corporate
Finance

Richard Chambers -
ECM
 
                020 7220 0500

 

Flagstaff Strategic and Investor
Communications
020 7129 1474

Tim Thomson/Andrea Seymour/Fergus Melon
 
byotrol@flagstaffcomms.com

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and
control company, operating globally in the animal health, human health,
facilities management, and consumer sectors.

 

Byotrol develops unique antimicrobial technologies for use on surfaces, skin
and instruments, which it then commercialises through market-leading
distribution partners in each sector.

 

Byotrol's antimicrobial technologies can be licensed for use in leading
brands, to significantly improve their product claims, while reassuring
consumers and end-users of their efficacy and quality.

 

Founded in 2005, the Company develops technologies and products with the aim
of providing easier, safer and cleaner lives for everyone.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKBBQFBKKOCK